541 related articles for article (PubMed ID: 19584157)
1. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
[TBL] [Abstract][Full Text] [Related]
2. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.
Desmetz C; Bibeau F; Boissière F; Bellet V; Rouanet P; Maudelonde T; Mangé A; Solassol J
J Proteome Res; 2008 Sep; 7(9):3830-7. PubMed ID: 18683965
[TBL] [Abstract][Full Text] [Related]
3. Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis.
Tamesa MS; Kuramitsu Y; Fujimoto M; Maeda N; Nagashima Y; Tanaka T; Yamamoto S; Oka M; Nakamura K
Electrophoresis; 2009 Jun; 30(12):2168-81. PubMed ID: 19582718
[TBL] [Abstract][Full Text] [Related]
4. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma.
Fujita Y; Nakanishi T; Hiramatsu M; Mabuchi H; Miyamoto Y; Miyamoto A; Shimizu A; Tanigawa N
Clin Cancer Res; 2006 Nov; 12(21):6415-20. PubMed ID: 17085654
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
[TBL] [Abstract][Full Text] [Related]
6. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
[TBL] [Abstract][Full Text] [Related]
7. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
Lacombe J; Mangé A; Bougnoux AC; Prassas I; Solassol J
Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1834-42. PubMed ID: 24957886
[TBL] [Abstract][Full Text] [Related]
8. Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast cancer.
López-Árias E; Aguilar-Lemarroy A; Felipe Jave-Suárez L; Morgan-Villela G; Mariscal-Ramírez I; Martínez-Velázquez M; Alvarez AH; Gutiérrez-Ortega A; Hernández-Gutiérrez R
Electrophoresis; 2012 Jul; 33(14):2130-7. PubMed ID: 22821488
[TBL] [Abstract][Full Text] [Related]
9. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients.
Shih NY; Lai HL; Chang GC; Lin HC; Wu YC; Liu JM; Liu KJ; Tseng SW
Jpn J Clin Oncol; 2010 Jul; 40(7):663-9. PubMed ID: 20395242
[TBL] [Abstract][Full Text] [Related]
10. Identification of mammaglobin as a novel serum marker for breast cancer.
Bernstein JL; Godbold JH; Raptis G; Watson MA; Levinson B; Aaronson SA; Fleming TP
Clin Cancer Res; 2005 Sep; 11(18):6528-35. PubMed ID: 16166429
[TBL] [Abstract][Full Text] [Related]
11. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
Reinholz MM; Nibbe A; Jonart LM; Kitzmann K; Suman VJ; Ingle JN; Houghton R; Zehentner B; Roche PC; Lingle WL
Clin Cancer Res; 2005 May; 11(10):3722-32. PubMed ID: 15897569
[TBL] [Abstract][Full Text] [Related]
13. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
[TBL] [Abstract][Full Text] [Related]
14. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
Regele S; Kohlberger P; Vogl FD; Böhm W; Kreienberg R; Runnebaum IB
Br J Cancer; 1999 Oct; 81(4):702-4. PubMed ID: 10574259
[TBL] [Abstract][Full Text] [Related]
15. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
16. Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis.
Yi JK; Chang JW; Han W; Lee JW; Ko E; Kim DH; Bae JY; Yu J; Lee C; Yu MH; Noh DY
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1357-64. PubMed ID: 19423516
[TBL] [Abstract][Full Text] [Related]
17. HLA-G is a potential tumor marker in malignant ascites.
Singer G; Rebmann V; Chen YC; Liu HT; Ali SZ; Reinsberg J; McMaster MT; Pfeiffer K; Chan DW; Wardelmann E; Grosse-Wilde H; Cheng CC; Kurman RJ; Shih IeM
Clin Cancer Res; 2003 Oct; 9(12):4460-4. PubMed ID: 14555519
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
19. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.
Roessler M; Rollinger W; Palme S; Hagmann ML; Berndt P; Engel AM; Schneidinger B; Pfeffer M; Andres H; Karl J; Bodenmüller H; Rüschoff J; Henkel T; Rohr G; Rossol S; Rösch W; Langen H; Zolg W; Tacke M
Clin Cancer Res; 2005 Sep; 11(18):6550-7. PubMed ID: 16166432
[TBL] [Abstract][Full Text] [Related]
20. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women.
Frenkel K; Karkoszka J; Glassman T; Dubin N; Toniolo P; Taioli E; Mooney LA; Kato I
Cancer Epidemiol Biomarkers Prev; 1998 Jan; 7(1):49-57. PubMed ID: 9456243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
